Back to available technologies

Vaccination against an oncogenic isoform of HER2 (ErbB2) to prevent and treat HER2+ cancer

Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is 5 correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or 10 prevention agent or a checkpoint inhibitor immunomodulatory agent.

Duke File (IDF) Number



  • Lyerly, Herbert "Kim"
  • Hardman, Zach
  • Osada, Takuya

For more information please contact


School of Medicine (SOM)